Catalyst Event
Alnylam Pharmaceuticals Inc (ALNY) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/24/2026, 12:00:00 AM
Alnylam announced strategic collaborations with Viz.ai and the American Heart Association to accelerate diagnosis and improve care for ATTR-CM, a progressive heart condition, during a webinar on 2026-03-24; this major partnership is expected to drive a >10% price impact through market expansion and is scheduled.
Korean Translation
2026-03-24 웨비나에서 진행성 심장 질환인 ATTR-CM의 진단 가속화 및 치료 개선을 위한 Viz.ai 및 미국심장협회와의 전략적 협력을 발표함. 대규모 파트너십에 따른 10% 이상의 주가 상승이 예상되어 중요도를 높게 평가하며 예정됨.
Related Recent Events
Novo Nordisk A/S (NVO) · Other
Announced on Feb 24, 2026, that it will lower the U.S. list prices of key drugs Wegovy and Ozempic by approximately 50% and 35% respectively, effective January 1, 2027, to improve patient access.
1/1/2027, 12:00:00 AM
Novartis AG (NVS) · Other
Results from the Phase III Lp(a)HORIZON study of cardiovascular candidate pelacarsen are scheduled for 2026-06-30; this key clinical readout is estimated to have a >5% price impact expected.
6/30/2026, 12:00:00 AM
RELX PLC (RELX) · Other
Ex-dividend date for the 48.0 pence per share final dividend for fiscal year 2025 on May 7, 2026; dividend-related price adjustments are typically low, scheduled
5/7/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release is scheduled.
5/6/2026, 12:00:00 AM
Leidos Holdings Inc (LDOS) · Earnings Release
Leidos is scheduled to release Q1 2026 financial results on May 5, 2026, with analysts forecasting EPS of $2.91-$2.94 expected.
5/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer's Q1 2026 earnings release is scheduled for May 5, 2026, scheduled.
5/5/2026, 12:00:00 AM